Jose A Muñoz-Moreno1, Anna Prats, Núria Pérez-Álvarez, Carmina R Fumaz, Maite Garolera, Eduardo Doval, Eugènia Negredo, Maria J Ferrer, Bonaventura Clotet. 1. *Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; †Universitat Autònoma de Barcelona, Bellaterra, Spain; ‡Universitat Politècnica de Catalunya, Barcelona, Spain; §Consorci Sanitari Hospital de Terrassa, Terrassa, Spain; ‖Universitat de Barcelona, Grup de Recerca Consolidat en Neuropsicologia, Barcelona, Spain; and ¶Institut per la Recerca de la SIDA, Fundació IrsiCaixa, Badalona, Spain.
Abstract
OBJECTIVE: Practical screening methods are necessary to detect neurocognitive impairment (NCI) in HIV-infected patients. We aimed to find a brief and feasible paper-based tool to facilitate the diagnosis of an HIV-associated neurocognitive disorder. METHODS: A total of 106 HIV-infected outpatients with variable clinical characteristics were recruited in a multicenter investigation. NCI was diagnosed using a standardized neuropsychological tests battery (7 areas, 21 measures, ∼2 hours). Multiple score combinations were compared to find a paper-based method that took ≤10 minutes to apply. The presence of NCI was considered the gold standard for comparisons, and the sensitivity and specificity were calculated. RESULTS: Subjects were mostly middle-aged (median, 44 years) men (87%) on antiretroviral treatment. NCI was detected in 51 individuals (48%) and was associated with lower nadir CD4 count (P < 0.001), receiving antiretroviral therapy (P = 0.004), fewer years of education (P = 0.009), and presence of comorbidities (P < 0.001). The score combination that showed the highest sensitivity (74.5%) and specificity (81.8%) detecting NCI included 3 measures of attention/working memory, executive functioning, and verbal fluency (part A of Trail Making Test, part B of Trail Making Test, and Controlled Oral Word Association Test scores). A broader paper-based selection of measures covering 7 areas indicated a sensitivity of 100% and a specificity of 96.3% (7 measures, ∼35 minutes). CONCLUSIONS: The combination of the 3 measures presented in this study seems to be a rapid and feasible screening mean for NCI in HIV-infected patients. This approach, combined with screening for potential comorbidities and daily functioning interference, could help in the initial stages of a HIV-associated neurocognitive disorder diagnosis and in settings with limited access to neuropsychological resources.
OBJECTIVE: Practical screening methods are necessary to detect neurocognitive impairment (NCI) in HIV-infectedpatients. We aimed to find a brief and feasible paper-based tool to facilitate the diagnosis of an HIV-associated neurocognitive disorder. METHODS: A total of 106 HIV-infected outpatients with variable clinical characteristics were recruited in a multicenter investigation. NCI was diagnosed using a standardized neuropsychological tests battery (7 areas, 21 measures, ∼2 hours). Multiple score combinations were compared to find a paper-based method that took ≤10 minutes to apply. The presence of NCI was considered the gold standard for comparisons, and the sensitivity and specificity were calculated. RESULTS: Subjects were mostly middle-aged (median, 44 years) men (87%) on antiretroviral treatment. NCI was detected in 51 individuals (48%) and was associated with lower nadir CD4 count (P < 0.001), receiving antiretroviral therapy (P = 0.004), fewer years of education (P = 0.009), and presence of comorbidities (P < 0.001). The score combination that showed the highest sensitivity (74.5%) and specificity (81.8%) detecting NCI included 3 measures of attention/working memory, executive functioning, and verbal fluency (part A of Trail Making Test, part B of Trail Making Test, and Controlled Oral Word Association Test scores). A broader paper-based selection of measures covering 7 areas indicated a sensitivity of 100% and a specificity of 96.3% (7 measures, ∼35 minutes). CONCLUSIONS: The combination of the 3 measures presented in this study seems to be a rapid and feasible screening mean for NCI in HIV-infectedpatients. This approach, combined with screening for potential comorbidities and daily functioning interference, could help in the initial stages of a HIV-associated neurocognitive disorder diagnosis and in settings with limited access to neuropsychological resources.
Authors: Lewis J Haddow; Cristina Dudau; Hoskote Chandrashekar; Jonathan D Cartledge; Harpreet Hyare; Robert F Miller; H Rolf Jäger Journal: AIDS Patient Care STDS Date: 2014-05-01 Impact factor: 5.078
Authors: Hetta Gouse; Martine Casson-Crook; Eric H Decloedt; John A Joska; Kevin G F Thomas Journal: J Neurovirol Date: 2017-07-26 Impact factor: 2.643
Authors: Enrique López; Alexander J Steiner; Kimberly Smith; Nicholas S Thaler; David J Hardy; Andrew J Levine; Hussah T Al-Kharafi; Cristina Yamakawa; Karl Goodkin Journal: Appl Neuropsychol Adult Date: 2016-08-15 Impact factor: 2.248
Authors: Montserrat Sanmarti; Laura Ibáñez; Sonia Huertas; Dolors Badenes; David Dalmau; Mark Slevin; Jerzy Krupinski; Aurel Popa-Wagner; Angeles Jaen Journal: J Mol Psychiatry Date: 2014-03-04